RIFADIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rifadin, and when can generic versions of Rifadin launch?
Rifadin is a drug marketed by Sanofi Aventis Us and is included in three NDAs.
The generic ingredient in RIFADIN is rifampin. There are nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the rifampin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rifadin
A generic version of RIFADIN was approved as rifampin by EPIC PHARMA LLC on May 28th, 1997.
Summary for RIFADIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Clinical Trials: | 35 |
| Patent Applications: | 6,837 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for RIFADIN |
| What excipients (inactive ingredients) are in RIFADIN? | RIFADIN excipients list |
| DailyMed Link: | RIFADIN at DailyMed |
Recent Clinical Trials for RIFADIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GlaxoSmithKline | Phase 2 |
| TASK Applied Science | Phase 2 |
| University of Cape Town | Phase 3 |
Pharmacology for RIFADIN
| Drug Class | Rifamycin Antibacterial |
US Patents and Regulatory Information for RIFADIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | RIFADIN | rifampin | CAPSULE;ORAL | 062303-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Sanofi Aventis Us | RIFADIN | rifampin | CAPSULE;ORAL | 050420-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Sanofi Aventis Us | RIFADIN | rifampin | INJECTABLE;INJECTION | 050627-001 | May 25, 1989 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
